beta1 integrin targeting to enhance radiation therapy.
OBJECTIVE
Cell adhesion to extracellular matrix (ECM) proteins is mediated by the integrin family and has been known to modify radiation sensitivity and resistance in several cell types, including cancer cells. In particular, beta1 integrin signaling has been implicated in the progression and metastasis of various cancers and has been shown to facilitate resistance to radiation therapy.


CONCLUSIONS
In this mini-review, we provide a brief overview of integrin targeting in radiation therapy. We specifically focus on the updated findings of beta1 integrin-mediated signaling pathways after exposure to ionising radiation (IR) using in vitro and in vivo experimental models, which could represent promising therapeutic targets for breast cancer.
Nam
Jin-Min
JM
Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, California 94143-1708, USA.
Chung
Yoonsun
Y
Hsu
Howard C
HC
Park
Catherine C
CC
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D019012:Integrin beta1 / Q000187:drug effects* / Q000502:physiology; D016023:Integrins / Q000037:antagonists & inhibitors / Q000502:physiology; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy*; D011836:Radiation Tolerance / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects / Q000528:radiation effects
D019012:Integrin beta1; D016023:Integrins